Form 6-K Ascendis Pharma A/S For: Sep 16
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
Go back to Form 6-K Ascendis Pharma A/S For: Sep 16
September 17, 2024 6:32 AM EDT
Evercore ISI analyst Josh Schimmer raised the price target on Ascendis Pharma (NASDAQ: ASND) to $205.00 (from $191.00) while maintaining a Outperform rating.
The analyst comments "Were still refining some estimates via HCP calls. For now, we model $450M peak TransCON CNP sales in achon. For... More
September 16, 2024 4:35 PM EDT
Jefferies analyst Kelly Shi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $179.00 (from $174.00) while maintaining a Buy rating.
The analyst comments "Co reported pivotal data from Navepegritide (TransCon CNP) in children w/ achondroplasia aged 2-11yo, which showed an... More
September 16, 2024 12:07 PM EDT
BofA Securities analyst Tazeen Ahmad reiterated a Buy rating and $175.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "ASND could be on its way to a third approved product using its long-acting TransCon technology. Today, it announced positive topline results for... More
September 16, 2024 12:06 PM EDT
Goldman Sachs analyst Paul Choi raised the price target on Ascendis Pharma (NASDAQ: ASND) to $200.00 (from $180.00) while maintaining a Buy rating.
The analyst comments "Topline ApproaCH data indicate clear clinical benefit for TransCon CNP and competitive efficacy/safety/convenience profile; looking to detailed data and... More
September 16, 2024 10:25 AM EDT
Stifel analyst Alex Thompson reiterated a Buy rating and $200.00 price target on Ascendis Pharma (NASDAQ: ASND).
The analyst comments "TransCon CNP succeeded in the Ph2/3 ApproaCH study in achondroplasia. On the primary endpoint of annualized growth velocity (AGV) the drug achieved a 1.49cm/yr delta vs. placebo (p... More
